Summary: A UCLA study shows that a new PET-CT imaging technique using 89Zr-TLX250 accurately detects clear-cell renal cell carcinoma, potentially reducing unnecessary surgeries and improving treatment timing.
Key Takeaways
- The new PET-CT imaging technique using 89Zr-TLX250 accurately detects clear-cell renal cell carcinoma with high sensitivity (85.5%) and specificity (87%), even in small tumors.
- This non-invasive method could reduce unnecessary surgeries and improve treatment timing for kidney cancer patients.
- The technique has the potential to become a new standard in kidney cancer diagnostics, with future trials aiming to explore its use in identifying metastatic disease.
—————————————————————————————————————————————————————————————
A new study from the University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center has shown that a non-invasive imaging technique can accurately detect clear-cell renal cell carcinoma, the most common and deadly form of kidney cancer.
Published in The Lancet Oncology, this approach could reduce unnecessary surgeries and improve treatment timing. Brian Shuch, MD, director of the Kidney Cancer Program at UCLA, emphasized the importance of early detection, noting that “if caught early, over 90% of patients can survive for at least five years.” Traditional imaging methods like CT and MRI often struggle to distinguish between benign and malignant tumors, leading to unnecessary interventions or delayed treatment.
High Accuracy in Detecting Kidney Cancer
The research team tested a new method using the monoclonal antibody drug 89Zr-TLX250, which targets the CA9 protein commonly found in clear-cell renal cell carcinoma. In the phase 3 ZIRCON trial, 332 patients from nine countries were injected with 89Zr-TLX250, and PET-CT scans were used to detect cancer. This imaging accurately identified cancer with an 85.5% sensitivity and 87% specificity, even in small renal masses less than 2 cm.
Shuch says, “The implications of this research are vast,” suggesting that 89Zr-TLX250 PET-CT imaging could become the new standard in kidney cancer diagnostics. Future clinical trials aim to determine if this technique can also identify metastatic disease, potentially guiding treatment plans more effectively and sparing patients from unnecessary therapies.
